MedTrace Logo

Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning

NCT02952716 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-18

No results posted yet for this study

Summary

The effects and safety of Human cord blood mononuclear cell for delayed encephalopathy after carbon monoxide poisoning

Conditions

  • Delayed Encephalopathy After Carbon Monoxide Poisoning

Interventions

BIOLOGICAL

Human cord blood mononuclear cell

The patients were treated by human cord blood mononuclear cell through subarachnoid space

OTHER

hyperbaric oxygen

The patients were treated by hyperbaric oxygen

Sponsors & Collaborators

  • Liaocheng People's Hospital

    lead OTHER

Principal Investigators

  • Shuangfeng Chen, Ph.D. · Liaocheng People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-10-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02952716 on ClinicalTrials.gov